Sanibel Captiva Trust Company Inc. Boosts Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Sanibel Captiva Trust Company Inc. increased its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 8.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,605 shares of the company’s stock after buying an additional 1,477 shares during the period. Sanibel Captiva Trust Company Inc.’s holdings in AstraZeneca were worth $1,285,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Stratos Wealth Advisors LLC lifted its holdings in AstraZeneca by 2.0% during the 3rd quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company’s stock worth $522,000 after buying an additional 133 shares in the last quarter. Crumly & Associates Inc. increased its position in shares of AstraZeneca by 2.2% during the third quarter. Crumly & Associates Inc. now owns 6,644 shares of the company’s stock worth $518,000 after acquiring an additional 143 shares during the period. Harbour Investments Inc. raised its stake in shares of AstraZeneca by 1.9% in the third quarter. Harbour Investments Inc. now owns 8,805 shares of the company’s stock valued at $686,000 after acquiring an additional 160 shares in the last quarter. Smith Salley Wealth Management boosted its holdings in AstraZeneca by 1.0% in the third quarter. Smith Salley Wealth Management now owns 16,158 shares of the company’s stock valued at $1,259,000 after purchasing an additional 162 shares during the period. Finally, Veracity Capital LLC grew its stake in AstraZeneca by 4.5% during the 3rd quarter. Veracity Capital LLC now owns 3,833 shares of the company’s stock worth $299,000 after purchasing an additional 164 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Stock Down 0.5 %

AZN stock opened at $66.60 on Friday. The company’s 50 day moving average is $66.11 and its two-hundred day moving average is $74.49. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. The stock has a market cap of $206.50 billion, a P/E ratio of 31.87, a PEG ratio of 1.05 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The company had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. During the same quarter in the prior year, the firm posted $0.87 earnings per share. AstraZeneca’s revenue for the quarter was up 18.0% on a year-over-year basis. Research analysts expect that AstraZeneca PLC will post 4.11 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

AZN has been the subject of several recent research reports. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.